Issue No. 806 (dated 7/2/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS, #ANTH, #BMRN, #ISIS, #MDCO
Tag: ANTH
MTSL Issue #802 – Upgrading INCY & Time To Drink The Nektar
Medical Technology Stock Letter – Issue #802: Upgrading INCY & Time To Drink The Nektar
Anthera Update (3-17-15)
Anthera Update (3-17-15)
MTSL Issue #774 – The Beat Goes On, But Not Without Skipping A Beat Or Two
March 6, 2014 Below is a pdf for MTSL Issue #774 of the Medical Technology Stock Letter.
MoneyShow: Biotech Catalysts (6-22-15)
Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.
MTSL Issue #801 – Anthera Getting Clearer Tasting CHABLIS
Medical Technology Stock Letter – Issue #801: Anthera Getting Clearer Tasting CHABLIS $ANTH
Biotech Fund Managers – What The Pros Do Every Year
August 21, 2014 The Medical Technology Stock Letter (“MTSLâ€) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time†because that is the nature of drug development and compounded returns of successful biotech stocks over the years vastly exceed that of the overall market. […]
Anthera Update (1-19-13)
Anthera announced last week that they priced a public offering of 60 million shares at $0.66 per share, which will add $40 million to their balance sheet. Jefferies is acting as sole book-running manager in the offering and Leerink Swann is acting as co-manager. These are quality investment banks and it is an impressive accomplishment for[…]
MTSL Issue 805
Issue No. 805 (dated 6/11/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #CBMG, #IMGN, #INCY, #ISIS, #MDCO, #NKTR, #OGXI, #ZIOP
MoneyShow: A Trio of Biotech Favorites (4-6-15)
Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.
A BRIEF IMMUNE-ONCOLOGY UPDATE
June 12, 2014 ASCO 2014 â Immune Oncology Rises to the Top â As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting. While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by Merck, and Roche. At[…]
Anthera Update (1-18-13)
Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year. ANTH now says that that they are[…]